Belly Koren
Technion – Israel Institute of Technology
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Belly Koren.
Circulation | 2001
Anat Weisz; Belly Koren; Tzafra Cohen; Gera Neufeld; Tamar Kleinberger; Basil S. Lewis; Moshe Y. Flugelman
BackgroundThe angiogenic effect of vascular endothelial growth factor (VEGF165) is mediated mainly through the high-affinity tyrosine kinase receptor VEGF-R2 (KDR/ flk-1). This study examined the effects of VEGF overexpression by primary human endothelial cells (ECs), which do not express VEGF under physiological conditions, on cell proliferation, VEGF binding to the kinase insert domain-containing receptor (KDR), and KDR expression. Methods and ResultsHuman primary ECs and SMCs were infected by recombinant adenoviral vector encoding VEGF165 (rAdVEGF). Proliferation rate, bromodeoxyuridine incorporation, 125I-labeled VEGF165 binding to the KDR receptor, and KDR expression were tested in the infected cells and in cells supplemented with VEGF protein. Enhanced proliferation and a significant increase in 125I-VEGF165 binding to the KDR receptor were induced by rAdVEGF infection of ECs (autocrine effect) as well as by addition of recombinant VEGF165 to noninfected cells. Infection of ECs by rAdVEGF led to posttranscriptional upregulation of the KDR receptor, whereas KDR mRNA expression levels remained unchanged. Similar effects were observed with supplemented recombinant VEGF165 to noninfected ECs; nevertheless, this phenomenon occurred only with high VEGF165 concentrations (10 ng/mL). ConclusionsThe effect of VEGF165 on proliferation and upregulation of KDR receptor expression demonstrated an autocrine phenomenon of EC sensitization. The fact that high concentrations of VEGF may be achieved in vivo by local continuous overexpression of VEGF165 by gene transfer emphasizes the potential advantage of gene transfer over protein supplementation for therapeutic angiogenesis.
Biochemical and Biophysical Research Communications | 2006
Meir Preis; Tzafra Cohen; Y. Sarnatzki; Y. Ben Yosef; J. Schneiderman; Zoya Gluzman; Belly Koren; Basil S. Lewis; Yosef Shaul; Moshe Y. Flugelman
Biochemical and Biophysical Research Communications | 2007
Zoya Gluzman; Belly Koren; Meir Preis; Tzafra Cohen; Adili Tsaba; François-Loïc Cosset; Rona Shofti; Basil S. Lewis; Renu Virmani; Moshe Y. Flugelman
Cardiovascular Revascularization Medicine | 2006
Belly Koren; Anat Weisz; Lukas Fischer; Zoya Gluzman; Meir Preis; Naomi A. Avramovitch; Tzafra Cohen; François-Loïc Cosset; Basil S. Lewis; Moshe Y. Flugelman
Archive | 2001
Moshe Y. Flugelman; Meir Preis; Zoya Gluzman; Belly Koren; Anat Weisz; Tzafra Cohen
Archive | 2002
Moshe Y. Flugelman; Zoya Gluzman; Meir Preis; Belly Koren; Tzafra Cohen; Adili Tsaba; Michael Ott
Molecular Therapy | 2017
Moshe Y. Flugelman; Moshe Halak; Boris Yoffe; Jacob Schneiderman; Chen Rubinstein; Allan-Isaac Bloom; Eran Weinmann; Ilya Goldin; Victor Ginzburg; Olga Mayzler; Aaron Hoffman; Belly Koren; Diana Gershtein; Michal Inbar; Marina Hutoran; Adili Tsaba
Archive | 2003
Moshe Y. Flugelman; Zoya Gluzman; Meir Preis; Belly Koren; Tzafra Cohen; Adili Tsaba; Anat Weisz
Israel Medical Association Journal | 2000
Anat Weisz; Belly Koren; Lukas Fischer; Basil S. Lewis; Moshe Y. Flugelman
Archive | 2001
Tzafra Cohen; Moshe Y. Flugelman; Zoya Gluzman; Belly Koren; Meir Preis; Adili Tsaba; Anat Weisz